Bionano Genomics, Inc. (BNGO) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Bionano Genomics, Inc. for the period ended March 31, 2026. The Company provides optical genome mapping (OGM) solutions, diagnostic services, and software. As of the reporting date, the Company is classified as a non-accelerated filer and a smaller reporting company. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $6.69 million | $6.46 million |
| Net Loss | $(8.30) million | $(3.10) million |
| Net Loss Per Share (Basic/Diluted) | $(0.76) | $(1.15) |
| Gross Margin (Total) | 49% | 46% |
| Operating Cash Flow | $(5.72) million | $(2.76) million |
| Cash & Cash Equivalents | $3.43 million | $3.63 million |
| Short-Term Investments | $11.0 million | $16.3 million |
| Restricted Cash & Investments | $10.3 million | $10.3 million |
| Convertible Debentures (Fair Value) | $10.15 million | $9.98 million |
| Accumulated Deficit | $(727.9) million | $(696.3) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4% year-over-year, driven by a 40% increase in instrument revenue ($0.96M vs $0.69M) and a 20% increase in consumables revenue ($3.90M vs $3.25M). Software revenue declined 40% to $1.23M.
- Expense Fluctuations: Research and Development (R&D) expenses rose 32% to $3.14M due to increased headcount and professional fees. Selling, General, and Administrative (SG&A) expenses decreased 11% to $8.01M, primarily due to reduced stock-based compensation and professional fees.
- Net Loss Expansion: Net loss widened significantly to $8.30M from $3.10M. This was largely driven by a reversal of "Other Income" to "Other Expense" of $0.62M (compared to $5.08M income in Q1 2025), attributed to changes in the fair value of convertible debentures.
- Installed Base: The global installed base of OGM systems grew to 399 units, a 5% increase from 379 units in Q1 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the next 12 months. The Company expects to continue incurring operating losses and negative cash flows.
- Liquidity Needs: With approximately $3.4 million in unrestricted cash and $11.0 million in short-term investments (plus restricted funds), the Company states it will require additional capital in the very near term to fund operations. Failure to secure financing could lead to curtailment of operations or bankruptcy proceedings.
- Debt Obligations: The Company holds $10.3 million in principal outstanding under Senior Secured Convertible Debentures maturing May 24, 2026. These debentures require the Company to maintain a restricted cash balance equal to the lesser of $11.0 million or the outstanding principal.
- Capital Raising: The Company is actively evaluating debt and equity financing sources. It recently filed a new universal shelf registration statement to replace an expiring one, allowing for future offerings of up to $400 million in securities.
- Geopolitical Risks: The Company noted a slowdown in Asia Pacific business due to headwinds affecting manufacturing partners reliant on government funding.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current unrestricted cash ($3.4M) against monthly burn rates and the timeline for securing new financing.
- Debt Maturity: Confirm the repayment plan for the $10.3M convertible debentures maturing in May 2026 and the impact of the required restricted cash balance on liquidity.
- Revenue Mix: Monitor the sustainability of the 40% decline in software revenue and the reliance on consumable sales for recurring revenue.
- Going Concern Status: Review subsequent filings for updates on capital raising efforts or potential restructuring/bankruptcy proceedings.
- Stock-Based Compensation: Assess the impact of recent executive option grants and the reduction in stock-based compensation on future expense structures.